ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Recommended HIV postexposure prophylaxis (PEP) for percutaneous injuries

Recommended HIV postexposure prophylaxis (PEP) for percutaneous injuries
Exposure type Infection status of source
HIV-positive class 1* HIV-positive class 2* Source of unknown HIV status Unknown sourceΔ HIV-negative
Less severe◊ Recommend basic 2 drug PEP Recommend expanded ≥3 drug PEP Generally, no PEP warranted; however, consider basic 2-drug PEP§ for source with HIV risk factors¥ Generally, no PEP warranted; however, consider basic 2-drug PEP§ in settings in which exposure to HIV-infected persons is likely No PEP warranted
More severe§ Recommend expanded ≥3 drug PEP Recommend expanded ≥3 drug PEP Generally, no PEP warranted; however, consider basic 2-drug PEP§ for source with HIV risk factors¥ Generally, no PEP warranted; however, consider basic 2-drug PEP§ in settings in which exposure to HIV-infected persons is likely No PEP warranted
* HIV-positive, Class 1: asymptomatic HIV infection or known low viral load (eg, <1500 ribonucleic acid copies/mL). HIV-positive, Class 2: symptomatic HIV infection, acquired immunodeficiency syndrome, acute seroconversion, or known high viral load. If drug resistance is a concern, obtain expert consultation. Initiation of PEP should not be delayed pending expert consultation, and, because expert consultation alone cannot substitute for face-to-face counseling, resources should be available to provide immediate evaluation and follow-up care for all exposures.
¶ For example, deceased source person with no samples available for HIV testing.
Δ For example, a needle from a sharps disposal container.
◊ For example, solid needle or superficial injury.
§ The recommendation "consider PEP" indicates that PEP is optional; a decision to initiate PEP should be based on a discussion between the exposed person and the treating clinician regarding the risks versus benefits of PEP.
¥ If PEP is offered and administered and the source is later determined to be HIV-negative, PEP should be discontinued.
MMWR Recomm Rep 2005; 54(RR-9):1.
Graphic 58487 Version 3.0